Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001875620-25-000020
Filing Date
2025-08-13
Accepted
2025-08-13 11:12:23
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10238
2 JOINT FILING STATEMENT jointfilingstatementscvp.htm EX-1 5263
  Complete submission text file 0001875620-25-000020.txt   17238
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Subject) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)